Working Together on a New Future in Cancer Therapy
TILT Biotherapeutics (Tiltbio) is the world’s leading company developing investigational oncolytic immunotherapies to enable T-cell therapy of solid tumors, with ovarian cancer as our lead indication.
We collaborate with industry-leading pharmaceutical companies to enhance the therapeutic efficacy of in-development cancer immunotherapies by stimulating T cells with our TILT® technology.
Tiltbio’s current partnerships include:
- Merck & Co., Inc. (US) for pembrolizumab (KEYTRUDA®) in ovarian and lung cancer studies.
- Merck KGgA (Germany) for avelumab in combination with TILT-123 for head and neck cancer studies.
As part of Tiltbio’s partnership strategies, clinical collaborations are critical for generating data on combination therapies. In addition, Tiltbio’s patented technology will be available for licensing to support the commercialization of its pipeline.
TILT® technology can be a valuable asset for the immune-oncology pipeline of big pharmaceutical companies.
To learn more about partnership opportunities with Tiltbio, please contact bd@tiltbio.com.